Polynovo (ASX:PNV) Short Interest


ASX:PNV Polynovo Ltd ASX:PNV
76 GF Score
Price A$0.91
GF Value A$3.24
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:PNV vs ABT, SYK, MDT: Short Interest Comparison

For the Medical Devices subindustry, Polynovo's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polynovo Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Short Interest distribution charts can be found below:

* The bar in red indicates where Polynovo's Short Interest falls into.


ASX:PNV
76GF Score
Polynovo Ltd ASX:PNV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Polynovo (ASX:PNV) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of A$0.91 is trading 71.9% below its estimated GF Value™ of A$3.24. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for ASX:PNV:

  • Short Interest:
  • GF Value™: A$3.24 vs. price of A$0.91 (71.9% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Other Exchanges CALZF:USAMFJ:Germany
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score

Get the complete analysis for ASX:PNV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.91
Price
A$3.24
GF Value